

March 1, 2018

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub:- Rating by S&P Global Ratings

With reference to the above subject, we have to inform you that our credit rating has been revised by S&P Global Ratings from 'BB' to 'BB-' as part of their review cycle. They have revised the outlook from 'Negative' to 'Stable'.

In addition, they have revised the rating on the senior unsecured notes issued in 2016 from 'BB' to 'BB-'.

Kindly find enclosed rating research update issued by S&P Global for your reference.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

RatingsDirect®

Research Update:

Glenmark Pharmaceuticals Downgraded To 'BB-' On Continuing Weak Operating Performance; Outlook Stable

Primary Credit Analyst:

Ashutosh Sharma, ACA, Singapore (65) 6239-6307; ashutosh.sharma@spglobal.com

Secondary Contact:

Vishal Kulkarni, CFA, Singapore (65) 6216-1047; vishal.kulkarni@spglobal.com

Table Of Contents

Overview

Rating Action

Rationale

Outlook

Ratings Score Snapshot

Related Criteria

Ratings List

Research Update:

Glenmark Pharmaceuticals Downgraded To 'BB-' On Continuing Weak Operating Performance; Outlook Stable

Overview

- India-based Glenmark's leverage is likely to remain elevated over the next 24 months due to the generic pharmaceutical company's weak operating performance.
- We believe weakness from severe pricing pressures in the U.S. market will continue to weigh on Glenmark, delaying a recovery in the company's financial position. The better operating performance of Glenmark's non-U.S. businesses will temper this weakness.
- We are lowering our long-term corporate credit rating on Glenmark to 'BB-' from 'BB'. We are also lowering our long-term issue rating on the company's senior unsecured notes to 'BB-' from 'BB'.
- The stable outlook reflects our view that Glenmark's FFO-to-debt ratio will be steady at 20%-25% over next 12-18 months supported by modest growth and stable EBITDA margins.

Rating Action

On March 1, 2018, S&P Global Ratings lowered its long-term corporate credit rating on India-based generic drugmaker Glenmark Pharmaceuticals Ltd. to 'BB-' from 'BB'. The outlook is stable. We also lowered our long-term issue rating on the company's senior unsecured notes to 'BB-' from 'BB'.

Rationale

The downgrade reflects our view that Glenmark's leverage is likely to remain elevated over the next 24 months due to the company's weak operating performance.

We estimate that Indian pharmaceutical companies such as Glenmark will continue to face severe pricing pressure and margin erosion in the U.S. generic drugs market, leading to an overall subdued operating performance. The better operating performance of Glenmark's non-U.S. businesses will temper this weakness. We believe the company's business is fairly well diversified.

We estimate that Glenmark's leverage measured by the ratio of funds from operations (FFO) to debt will be about 20% in fiscal 2019 (the year ending March 31, 2019). We estimate that Glenmark's leverage could improve to about 25% only by the end of fiscal 2020, provided the company significantly

improves its operating performance by launching new products or through potential out-licensing deals using its innovative pipeline.

Glenmark's revenue for the third quarter of fiscal 2018 fell by 13.1% while its EBITDA margins slid sharply to below 15.0%. A 40.2% year-over-year decline in U.S. sales largely overshadowed good growth momentum elsewhere. A large part of the decline in revenue and margin compression was also due to the lack of new product launches in fiscal 2018, after one-time exclusive Zetia sales in fiscal 2017. We expect the price erosion in the U.S. market to continue over the next 12-18 months.

We believe Glenmark has a strong slate of 18-20 products, which should help the company regain growth in fiscals 2019 and 2020, and push the EBITDA margin back to the 18%-20% range.

We expect Glenmark's working capital cycle to remain longer than that of most of its peers. This factor, coupled with continuing capital expenditure (capex) and novel drug related research and development expenses, is likely to limit deleveraging opportunities over the next 12-18 months. We estimate that the company's reported debt will broadly remain unchanged over the next two years.

Our base case for fiscal years 2019-2021 assumes the following:

- Glenmark's overall revenues to grow by 8%-10% in fiscal 2019 and by 13%-15% in fiscal 2020.
- Its U.S. revenues to be US\$500 million-US\$550 million, mainly driven by new product launches, even as prices of existing products decline by 5%-10%.
- The company's India business to grow faster, at 15%, owing to the launch of new products with a good presence in dermatology, respiratory and cardio-metabolic therapies.
- The Europe business to have steady growth of 15%-20% from new products and entry into new markets.
- Glenmark's EBITDA margin to be 18%-20%.
- Its capex to be Indian rupee (INR) 7.0 billion-INR8.0 billion annually.
- Its working capital investment to be INR3.0 billion-INR4.0 billion annually to support revenue growth.

Based on these assumptions, we arrive at the following credit measures over the next 12-24 months:

- Ratio of FFO to debt to remain at 20%-25%.
- Ratio of gross debt to EBITDA to remain at 2.2x-3.0x.
- Free operating cash flow to fluctuate between marginally negative to marginally positive.

Our base case for Glenmark assumes significant revenue contribution from the launch of new products. Any significant delay in these launches could further pressurize the company's leverage. Our estimates do not envisage any material adverse observations by the U.S. Food and Drug Administration (FDA) over the next 12-24 months.

Liquidity

We view Glenmark's liquidity as adequate. We expect the company's liquidity sources to exceed 1.2x its uses over the next 12 months. Net liquidity sources should remain positive even if EBITDA declines by 15%.

Glenmark maintains sound relationships with banks and has a fair standing in the local credit markets. We consider the company's financial management to be prudent because it has issued equity and addressed its refinancing needs on a timely basis.

Our liquidity estimates for the 12 months ending Dec. 31, 2018 are:

Key liquidity sources include:

- Cash balance of INR10.4 billion as of Dec. 31, 2017.
- Cash FFO of INR9.5 billion-INR10.5 billion.

Key liquidity uses include:

- Debt maturity of about INR7.0 billion.
- Negative working capital movement of INR3.0 billion-INR4.0 billion annually.
- Maintenance capex of INR3.0 billion annually.
- Dividends of up to INR800 million annually.

Outlook

Our stable outlook on Glenmark reflects our expectation that the company's FFO-to-debt ratio will be steady at 20%-25% over next 12-18 months supported by modest growth and stable EBITDA margins of 18%-20%. We also expect the company's liquidity to remain adequate over this period. In our base case, we do not foresee any new adverse U.S. FDA-related observations or proceedings.

Downside scenario

We may lower the rating if Glenmark's ratio of FFO to debt stays below 20% and free operating cash flows turn materially negative. This could happen if: (1) new product revenues fail to boost revenues and support margins; (2) working capital and capex increase significantly higher than our base case; or (3) the company engages in debt-fueled acquisitions or shareholder distributions.

Upside scenario

We may upgrade Glenmark if the ratio of FFO to debt approaches 30%. The company's revenue growing by close to 20% and EBITDA margins staying above 22%, supported by steady working capital and capex spending, could result in such a situation. Measures such as out-licensing and use of cash to reduce debt could lead to such improvement.

Ratings Score Snapshot

Corporate Credit Rating: BB-/Stable/--

Business risk: Weak

- Country risk: Intermediate risk
- Industry risk: Low risk
- Competitive position: Weak

Financial risk: Significant

- Cash flow/Leverage: Significant

Anchor: bb-

Modifiers

- Diversification/Portfolio effect: Neutral (no impact)
- Capital structure: Neutral (no impact)
- Liquidity: Adequate (no impact)
- Financial policy: Neutral (no impact)
- Management and governance: Fair (no impact)
- Comparable rating analysis: Neutral (no impact)

Stand-alone credit profile: bb-

Related Criteria

- Criteria - Corporates - General: Reflecting Subordination Risk In Corporate Issue Ratings, Sept. 21, 2017
- Criteria - Corporates - Recovery: Methodology: Jurisdiction Ranking Assessments, Jan. 20, 2016
- Criteria - Corporates - General: Methodology And Assumptions: Liquidity Descriptors For Global Corporate Issuers, Dec. 16, 2014
- Criteria - Corporates - Industrials: Key Credit Factors For The Pharmaceutical Industry, April 8, 2014
- Criteria - Corporates - General: Corporate Methodology, Nov. 19, 2013
- General Criteria: Country Risk Assessment Methodology And Assumptions, Nov. 19, 2013
- General Criteria: Methodology: Industry Risk, Nov. 19, 2013
- Criteria - Corporates - General: Corporate Methodology: Ratios And Adjustments, Nov. 19, 2013
- General Criteria: Group Rating Methodology, Nov. 19, 2013
- General Criteria: Methodology: Management And Governance Credit Factors For Corporate Entities And Insurers, Nov. 13, 2012
- General Criteria: Use Of CreditWatch And Outlooks, Sept. 14, 2009

Ratings List

Downgraded

	To	From
Glenmark Pharmaceuticals Ltd.		
Corporate Credit Rating	BB-/Stable/--	BB/Negative/--
Senior Unsecured	BB-	BB

Certain terms used in this report, particularly certain adjectives used to express our view on rating relevant factors, have specific meanings ascribed to them in our criteria, and should therefore be read in conjunction with such criteria. Please see Ratings Criteria at www.standardandpoors.com for further information. Complete ratings information is available to subscribers of RatingsDirect at www.capitaliq.com. All ratings affected by this rating action can be found on the S&P Global Ratings' public website at www.standardandpoors.com. Use the Ratings search box located in the left column.

Copyright © 2017 by Standard & Poor's Financial Services LLC. All rights reserved.

No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of Standard & Poor's Financial Services LLC or its affiliates (collectively, S&P). The Content shall not be used for any unlawful or unauthorized purposes. S&P and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P's opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P does not act as a fiduciary or an investment advisor except where registered as such. While S&P has obtained information from sources it believes to be reliable, S&P does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

To the extent that regulatory authorities allow a rating agency to acknowledge in one jurisdiction a rating issued in another jurisdiction for certain regulatory purposes, S&P reserves the right to assign, withdraw or suspend such acknowledgment at any time and in its sole discretion. S&P Parties disclaim any duty whatsoever arising out of the assignment, withdrawal or suspension of an acknowledgment as well as any liability for any damage alleged to have been suffered on account thereof.

S&P keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain business units of S&P may have information that is not available to other S&P business units. S&P has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P reserves the right to disseminate its opinions and analyses. S&P's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.ratingsdirect.com and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.

STANDARD & POOR'S, S&P and RATINGSDIRECT are registered trademarks of Standard & Poor's Financial Services LLC.